Eli Lilly has acquired Verve Therapeutics, a startup co-founded by Kiran Musunuru, MD, PhD, Professor of Medicine at Penn Medicine, to advance one-time gene-editing treatments to permanently reduce cardiovascular risk by targeting key cholesterol-related genes. Read more here. Access Musunuru’s interview about Verve and his research program here.